Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Pharma
Axsome's Sunosi scores in phase 3 ADHD trial
The positive ADHD data add to a string of recent wins for Axsome and comes ahead of an expected depression readout, William Blair analysts noted.
Kevin Dunleavy
Mar 25, 2025 11:46am
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
Teva looks to peel back the onion on mental health: exec
Dec 31, 2024 8:00am
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
Sanofi calls on 3 drugmakers to market its meds overseas
Mar 27, 2024 9:57am
Takeda, Eisai, GSK and more—Fierce Pharma Asia
Mar 31, 2023 8:27am
